$1.40
0.00%
Nasdaq, Oct 02, 09:30 am EDT.
ISIN
CA45783P1027
Symbol
INNPF

InnoCan Pharma Stock price

$1.40
-0.35 20.00% 1M
-3.55 71.72% 6M
-5.83 80.64% YTD
-11.13 88.83% 1Y
-13.12 90.36% 3Y
-58.40 97.66% 5Y
+0.91 185.71% 10Y
+0.91 185.71% 20Y
Nasdaq, Closing price Fri, Oct 02 2026
+0.00 0.00%
ISIN
CA45783P1027
Symbol
INNPF
Industry

Is InnoCan Pharma a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 9,120 stocks worldwide.

Key metrics

Basic
Market capitalization
$7.0m
Enterprise Value
$2.2m
Net debt
positive
Cash
$6.4m
Shares outstanding
4.5m
Valuation
P/E
negative
P/S | estimate
0.3 | -
EV/Sales | estimate
0.1 | -
EV/FCF | ex SBC
negative | negative
P/B
1.5
Financial Health
Equity Ratio
53.2%
Return on Equity
-20.1%
ROCE
-40.8%
ROIC
-91.8%
Debt/Equity
0.3
Share-Based Compensation & Dilution
SBC | % of Revenue
$1.5m | 6.3%
SBC as % of FCF
-
SBC Growth 1Y
148.3%
Share Count Growth 1Y
0.0%
Shareholder Yield
0.0%
Financials
Revenue | estimate
$23.5m | -
EBITDA
$-3.4m
EBIT
$-3.4m
Net Income
$-960.0k
Free Cash Flow | ex SBC
$-1.6m | $-3.0m
Growth
Revenue | estimate
-18.4% | -
EBITDA
-1,071.4%
EBIT
-1,179.9%
Net Income
39.2%
Free Cash Flow
-229.8%
Margin
Gross
90.5%
EBITDA
-14.4%
EBIT
-14.6%
Net
-4.1%
Free Cash Flow | ex SBC
-6.6% | -12.9%
More
EPS
$-0.2
FCF per Share
$-0.3
Short interest
-
Employees
-
Rev per Employee
-

Financial data from InnoCan Pharma

Jun '26
+/-
%
24 24
18% 18%
100%
- Direct Costs 2.25 2.25
32% 32%
10%
21 21
17% 17%
90%
- Selling and Administrative Expenses 24 24
30% 30%
102%
- Research and Development Expense 0.75 0.75
29% 29%
3%
-3.40 -3.40
1,071% 1,071%
-14%
- Depreciation and Amortization 0.04 0.04
33% 33%
0%
EBIT (Operating Income) EBIT -3.43 -3.43
1,180% 1,180%
-15%
Net Profit -0.96 -0.96
39% 39%
-4%

In millions USD.

Don't miss a Thing! We will send you all news about InnoCan Pharma directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Company Profile

InnoCan Pharma Corp. operates as a pharmaceutical tech company. Its segments include: Pharmaceuticals and Consumer Wellness. The Pharmaceuticals segment focuses on developing innovative drug delivery platform technologies based on advanced cannabinoids science. It involves two drug delivery technologies: LPT CBD- loaded liposome platform and CLX CBD-loaded exosomes platform. The Consumer Wellness segment develops and markets a wide portfolio of innovative and self-care products to promote a healthier lifestyle. The company was founded in October 2017 and is headquartered in Alberta, Canada.

Head office Canada
CEO Mrs. Bincovich
Founded 2018
Website innocanpharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today